Momelotinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 100 mg, 150 mg, 200 mg
Reference Brands: Ojjaara (USA)
Category:
Oncology Cancer Care
Momelotinib is available in Tablets
and strengths such as 100 mg, 150 mg, 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Momelotinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Momelotinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Momelotinib is an oral anticancer medication used for the treatment of myelofibrosis, a rare bone marrow disorder characterized by abnormal blood cell production, splenomegaly, and anemia. It is marketed under the brand name Ojjaara and belongs to the class of Janus kinase (JAK) inhibitors. Momelotinib works by inhibiting JAK1 and JAK2 signaling pathways involved in inflammation and abnormal cell proliferation, while also modulating pathways related to anemia, making it a differentiated therapy for patients with myelofibrosis.
Momelotinib is indicated for adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis and secondary myelofibrosis arising from polycythemia vera or essential thrombocythemia. The medication is administered orally, offering convenience for long-term disease management.
Common adverse reactions associated with momelotinib therapy include dizziness, fatigue, diarrhea, nausea, thrombocytopenia, hemorrhage, and bacterial infections. Due to these potential effects, patients receiving momelotinib require regular clinical and laboratory monitoring. Overall, momelotinib provides an important targeted treatment option for managing myelofibrosis, particularly in patients with disease-related anemia, supporting improved symptom control and quality of life.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing